Real-World Prevalence, Treatment Patterns, and Economic Impact of EGFR- and ALK-Targeted Therapies in Non-Small Cell Lung Cancer: A Nationwide Analysis from Greece
This nationwide analysis highlights the rapid adoption of second- and third-generation TKIs for EGFR- and ALK-positive NSCLC in Greece, reflecting evolving clinical practice patterns. Although the target patient populations are relatively small, the associated economic burden is considerable. To ensure long-term sustainability of the Greek healthcare system, policymakers should critically assess the cost-effectiveness of these innovative therapies and align resource allocation with value-based care principles.
Authors
- George Mavridoglou (ORCID: https://orcid.org/0000-0002-9357-4788)
- Anastasios Tsolakidis (ORCID: https://orcid.org/0000-0001-7364-4542)
- C. Tzanetakos
- Catherine Kastanioti (ORCID: https://orcid.org/0009-0001-8918-4592)
- Dikaios Voudigaris
- Theodore Kotsilieris (ORCID: https://orcid.org/0000-0003-3959-4531)
- George Gourzoulidis (ORCID: https://orcid.org/0000-0002-7239-9829)
- Konstantinos Mathioudakis (ORCID: https://orcid.org/0009-0001-4422-1521)
Institutions
- University of Peloponnese (GR)
- Center for Security Studies (GR)
Publication Details
- Journal
- Current Oncology
- Published
- 2025-09-27
- DOI
- https://doi.org/10.3390/curroncol32100542
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52